Urogen Pharma (NASDAQ:URGN) Receives $36.67 Average Price Target from Analysts

Urogen Pharma (NASDAQ:URGN) has earned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $36.6667.

A number of research firms have weighed in on URGN. Oppenheimer boosted their target price on shares of Urogen Pharma from $34.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Urogen Pharma in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. Finally, LADENBURG THALM/SH SH began coverage on Urogen Pharma in a report on Monday, May 11th. They set a “buy” rating and a $43.00 price objective for the company.

Institutional Trading of Urogen Pharma

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Urogen Pharma by 36.9% in the third quarter. JPMorgan Chase & Co. now owns 534,545 shares of the company’s stock valued at $10,664,000 after purchasing an additional 144,181 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Urogen Pharma in the third quarter valued at approximately $977,000. NEOS Investment Management LLC bought a new stake in shares of Urogen Pharma in the third quarter valued at approximately $1,007,000. Privium Fund Management B.V. raised its position in shares of Urogen Pharma by 82.7% in the third quarter. Privium Fund Management B.V. now owns 196,622 shares of the company’s stock valued at $3,923,000 after purchasing an additional 89,000 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its position in shares of Urogen Pharma by 148.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 161,924 shares of the company’s stock valued at $3,792,000 after purchasing an additional 96,741 shares during the period. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Stock Down 1.1%

URGN stock opened at $28.26 on Friday. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $32.37. The stock’s 50 day moving average is $22.10 and its 200-day moving average is $22.17. The firm has a market capitalization of $1.38 billion, a PE ratio of -10.28 and a beta of 1.58.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. On average, equities research analysts anticipate that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.